COMMUNIQUÉS West-GlobeNewswire

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
22/04/2026
MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March [...]
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
22/04/2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Glyco Harmony Drops Examined - 2026 Consumer-Focused Report on Ingredients, Claims & Label Insights
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Glyco Harmony Drops has been gaining attention among people looking for natural ways to support blood sugar balance without relying solely on traditional approaches. As [...]
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
22/04/2026
– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and [...]
Cue Biopharma Announces 1-for-30 Reverse Stock Split
22/04/2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
SRx Health Solutions Invests in Astro Investment XVII, an Affiliate of Astro Capital
22/04/2026
Company has invested greater than 10% of its investable capital in the convergence of Artificial Intelligence (“AI”) and space through Astro Capital NORTH PALM BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- SRx Health [...]
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
22/04/2026
PARIS, France – 22 April 2026 : Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster [...]
Mixlab and Instinct Partner to Transform Prescription Workflows for Veterinary Hospitals
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- As veterinary hospitals manage growing clinical complexity and administrative demands, workflow efficiency remains a key priority for both patient outcomes and team [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
22/04/2026
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Medicines360 and Pharma Dynamics announce the launch of Avibela® in South Africa, Expanding Access to Long‑Acting Contraception and Treatment of Heavy Menstrual Bleeding
22/04/2026
SAN FRANCISCO and CAPE TOWN, South Africa, April 22, 2026 (GLOBE NEWSWIRE) -- Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine [...]
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
22/04/2026
AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis
22/04/2026
Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis Paris, le 22 avril 2026 . La Food and Drug Administration (FDA) des États-Unis a prolongé de jusqu’à trois mois [...]
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026
Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 [...]
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026
Cette nomination renforce la gouvernance d'Elkedonia alors que la société poursuit son développement et prépare ses prochaines étapes de croissance Pierre d'Epenoux est l'ancien Président Directeur Général d'ImCheck [...]
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
22/04/2026
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda ® (tovorafenib) represents a rare [...]
Maze Therapeutics Announces $150 Million Registered Offering
22/04/2026
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a [...]
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026
Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d’Epenoux is former CEO of ImCheck Therapeutics, a clinical-stage biotech immuno- [...]
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
22/04/2026
 Nouvelle option thérapeutique pour des tumeurs cérébrales pédiatriques rares et potentiellement invalidantes Moins de 10 % des nouvelles autorisations de médicaments au cours des cinq dernières années ont porté sur des [...]

Pages